Now showing items 1-4 of 4

    • Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study 

      Linhares, Alexandre C.; Velázquez, F. Raúl; Pérez Schael, Irene; Sáez Llorens, Xavier; Abate, Héctor; Espinoza, Félix; López, Pío; Macías Parra, Mercedes; Ortega Barría, Eduardo; Rivera Medina, Doris Maribel; Rivera, Luis; Pavia Ruz, Noris; Núñez, Ernesto; Damaso, Silvia; Ruiz Palacios, Guillermo M.; De Vos, Béatrice; O'Ryan Gallardo, Miguel; Gillard, Paul; Bouckenooghe, Alain (ELSEVIER, 2008-04-05)
      Background Peak incidence of rotavirus gastroenteritis is seen in infants between 6 and 24 months of age. We therefore aimed to assess the 2-year efficacy and safety of an oral live attenuated human rotavirus vaccine for ...
    • Rotarix®: Vaccine performance 6 years postlicensure 

      O'Ryan Gallardo, Miguel; Lucero, Yalda; Linhares, Alexandre C. (2011)
      Rotarix® was first licensed in 2004 and rapidly introduced into private and public markets worldwide. In a previous 2009 article, we reviewed the impact of rotavirus-associated disease, the rationale for different vaccines, ...
    • Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis 

      Ruiz Palacios, Guillermo M.; Pérez Schael, Irene; Velázquez, F. Raúl; Abate, Héctor; Breuer, Thomas; Costa Clemens, SueAnn; Cheuvart, Brigitte; Espinoza, Félix; Gillard, Paul; Innis, Bruce L.; Cervantes, Yolanda; Linhares, Alexandre C.; López, Pío; Macías Parra, Mercedes; Ortega Barría, Eduardo; Richardson, Vesta; Rivera Medina, Doris Maribel; Rivera, Luis; Salinas, Belén; Pavia Ruz, Noris; Salmerón, Jorge; Rüttimann, Ricardo; Tinoco, Juan Carlos; Rubio, Pilar; Núñez, Ernesto; Guerrero, Lourdes; Yarzábal, Juan Pablo; Damaso, Silvia; Tornieporth, Nadia; Sáez Llorens, Xavier; Vergara, Rodrigo F.; Vesikari, Timo; Bouckenooghe, Alain; Clemens, Ralf; De Vos, Béatrice; O'Ryan Gallardo, Miguel (Massachusetts Medical Soc, 2006-01-05)
      BACKGROUND: The safety and efficacy of an attenuated G1P[8] human rotavirus (HRV) vaccine were tested in a randomized, double-blind, phase 3 trial. METHODS: We studied 63,225 healthy infants from 11 Latin American ...
    • Update on Rotarix™: An oral human rotavirus vaccine 

      O'Ryan Gallardo, Miguel; Linhares, Alexandre C. (2009)
      Worldwide, rotaviruses are the single most important agents of severe gastroenteritis in infants and young children. Globally, it is estimated that every year rotavirus gastroenteritis causes more than 125 million episodes ...